Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
1(14%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
3
43%
Ph phase_3
3
43%
Ph phase_1
1
14%

Phase Distribution

1

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
3(42.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(5)
Other(1)

Detailed Status

Completed5
unknown1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 23 (42.9%)
Phase 33 (42.9%)

Trials by Status

completed571%
unknown114%
recruiting114%

Recent Activity

1 active trials
Showing 5 of 7
recruitingphase_3

IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia

NCT07473960
completedphase_3

A Study of IBI306 in Participants With Hypercholesterolemia

NCT04709536
completedphase_2

Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia

NCT03815812
completedphase_3

Safety and Efficacy of IBI306 in HeFH Patients

NCT04179669
completedphase_2

A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia

NCT04031742
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07473960Phase 3

IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia

Recruiting
NCT04709536Phase 3

A Study of IBI306 in Participants With Hypercholesterolemia

Completed
NCT03815812Phase 2

Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia

Completed
NCT04179669Phase 3

Safety and Efficacy of IBI306 in HeFH Patients

Completed
NCT04031742Phase 2

A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia

Completed
NCT04948008Phase 2

Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia

Unknown
NCT03366688Phase 1

Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7